- CEO Stephen C. Glover to discuss important development status updates of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for kidney disease and Inflammasome ASC Inhibitor IC 100 for multiple CNS and other inflammatory diseases
WESTON, Fla., March 1, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. ZVSA or “ZyVersa”))), a specialty clinical-stage biopharmaceutical company developing first-in-class medicines to treat inflammatory and renal diseases with significant unmet medical needs, announced today that Stephen C. Glover, Co-Founder, Chairman, Chief Executive The officer and president will participate in a fireside chat at the 33rd Annual Oppenheimer Healthcare Conference, being held virtually March 13-15.
ZyVersa Fireside Chat details are as follows:
| Case: | 33rd Annual Oppenheimer Healthcare Conference | |
| Date: | Monday March 13, 2023 | |
| Time: | 11:20 a.m. EST | |
| Location: | Virtual –shortcut | |
“As a newly listed company on Nasdaq under the ticker ‘ZVSA’, we are pleased to discuss the potential of ZyVersa to enhance shareholder value as we advance the development of both of our platform technologies,” said Mr. Glover. “ZyVersa is currently developing two product candidates, Cholesterol Efflux MediatorTM VAR 200 in development to improve renal lipid accumulation, which damages the kidney’s filtration system, and the inflammasome ASC inhibitor IC 100, which blocks the onset and persistence of deleterious inflammation associated with numerous inflammatory diseases.”
To learn more about ZyVersa and its differentiated product pipeline, please request a virtual one-on-one with Mr. Glover via the conference portal.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical-stage, specialty biopharmaceutical company that uses advanced, proprietary technologies to develop world-class medicines. ZyVersa’s focus is on patients with kidney or inflammatory diseases who have significant unmet medical needs. The Company’s development pipeline includes Phase 2a-ready…
[ad_2]
Source story
